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Abstract  59 
Aims: International variations in visual acuity (VA) outcomes of eyes treated for neovascular age-related 60 
macular degeneration (nAMD) are well documented, but intra-country inter-centre regional variations are 61 
not known. This data is important for national quality outcome indicators. We aimed to determine intra-62 
country, inter-centre regional variations in outcomes for treatment of nAMD. 63 
Methods: Prospective multi-centre national database study of 13 UK centres that treated patients 64 
according to a set protocol (3 loading doses, followed by pro-re-nata re-treatment). 5,811 treatment naive 65 
eyes of 5,205 patients received a total of 36,206 ranibizumab injections over 12 months.  66 
Results: Mean starting VA between centres varied from 48.9 to 59.9 ETDRS letters. Mean inter-centre VA 67 
change from baseline to 12 months varied from +6.9 letters to -0.6 letters (mean of +2.5 letters). The 68 
proportion of eyes achieving VA of 70 letters or more varied between 21.9% and 48.7% at 12 months. 69 
Median number of injections (visits) at each centre varied from 5 to 8 (9 to 12) with an overall median of 6 70 
(11). Age, starting VA, number of injections and visits but not gender were significantly associated with 71 
variation in these VA outcomes (P<0.01). Significant variation between centres persisted even after 72 
adjusting for these factors.  73 
Conclusions:  There are modest differences in VA outcomes between centres in the UK. These differences 74 
are influenced, but not completely explained, by factors such as patient age, starting VA, number of 75 
injections and visits. These data provide an indication of the VA outcomes that are achievable in real world 76 
settings.     77 
 78 
Introduction 79 
Age-related macular degeneration (AMD) is one of the leading causes of irreversible blindness in patients 80 
aged over 60 years. Since the introduction of anti-Vascular Endothelial Growth Factor (VEGF) agents to 81 
treat neovascular AMD (nAMD) in 2006, rates of blindness and visual impairment from AMD have declined 82 
dramatically.1-3 Data from several randomized clinical trials suggest patients gain on average 6-11 letters 83 
using the most aggressive monthly dosing posology in the first year of treatment.4-7 A less resource 84 
intensive Pro-Re-Nata (PRN) dosing posology has been found in the Comparison of Age-related macular 85 
degeneration Treatment Trials (CATT)6;8 and Inhibit VEGF in Age-related choroidal Neovascularisation 86 
(IVAN)7;9 trials to produce outcomes similar to monthly dosing. This has provided a sound empirical basis 87 
for use of PRN posology in the National Health System (NHS) in the United Kingdom (UK).  88 
 89 
Although PRN dosing posology in theory is able to achieve excellent outcomes, ‘real-world’ studies have not 90 
matched the outcomes achieved in clinical trials.10-13 We have previously reported longitudinal results from 91 
a cohort of patients recruited from hospitals in the UK.10;11;14 Patients had standardised data recorded at 92 
the point of care into an Electronic Medical Record (EMR) system and the grouped national findings 93 
showed that PRN retreatment after 3 loading doses resulted in moderately stable vision.11 National data 94 
have also been reported from Australia for a treat and extend posology.15 International multi-country real 95 
life comparisons have reported some international differences in VA outcomes and treatment 96 
patterns,16which may be influenced by different reimbursement and health system structures. However, 97 
what remains unclear is how much, if any, intra-country inter-centre regional variation occurs. This data is 98 
obscured by aggregate national data, and is important as it permits understanding of the factors that 99 
influence outcomes in a real world setting and allows national quality benchmarks to be set. In this report 100 
we examine inter-centre variations in patient characteristics, the number of treatments delivered and their 101 
impact on visual outcomes in 13 geographically distinct UK centres.  102 
 103 
Methods 104 
Study Design 105 
The study design is described in detail in previous reports from the UK-nAMD Database Study group.10;11;14 106 
In brief, sites known to make comprehensive use of Electronic Medical Records (EMR) systems were 107 
contacted and requested to contribute data. Patient identifiers were completely removed and site and 108 
clinician data were pseudo-anonymised. On this basis an ethics committee determined that formal ethics 109 
approval was not required. The study was conducted in accordance with the declaration of Helsinki and the 110 
UK’s Data Protection Act. 111 
Study Centres 112 
Thirteen NHS hospitals that deliver ranibizumab AMD treatment services in England and Northern Ireland 113 
submitted data to this study. Each site is the sole NHS provider of nAMD care to their local population and 114 
very few patients switch between providers. Following NICE approval for the use of ranibizumab for nAMD 115 
in the NHS in August 2008 all sites used this drug almost exclusively, although prior to this date some sites 116 
offered limited treatment with bevacizumab. The study was initiated on 1st Feb 2012, all approvals and data 117 
extraction was performed by 02 April 2012. Data was delivered to the analysis team by the end of April 118 
2012.  119 
Data variables 120 
Analysis was restricted to treatment-naïve eyes undergoing ranibizumab therapy conforming to 3 monthly 121 
loading dose followed by PRN posology for nAMD that completed at least 12 months of follow up.  122 
In this report the ‘best-measured VA’ was the best VA with refraction or habitual correction and/or pinhole 123 
as measured on an ETDRS chart and expressed as LogMAR vision and ETDRS letters. The vast majority of 124 
sites measured VA with habitual correction rather than best-corrected refracted VA at all time points and 125 
used ETDRS charts. Analysis for eyes with very low VA was undertaken by substituting counting fingers (CF), 126 
hand movement (HM), and perception of light (PL) with 2.0, 2.3, and 2.7, respectively.  127 
We examined the outcome measures commonly reported in clinical trials (VA change from 0 to 12 months, 128 
proportion of eyes gaining and losing 15 ETDRS letters etc) as well as other measures such as VA change 129 
from 3 to 12 months and proportion of eyes achieving 70 ETDRS letters at 12 months (Snellen equivalent of 130 
20/40 or 6/12, driving equivalent in many jurisdictions).  131 
Statistical methods 132 
Medisoft Ophthalmology (Medisoft Limited, Leeds, UK) was the EMR system used for data extraction. Data 133 
for right and left eyes of patients who had had at least one intravitreal injection of ranibizumab for nAMD 134 
were extracted. Both STATA version 11 and SPSS version 19 were used to analyse data. Perl and R package 135 
ggplot2 was used for multivariable analyses, construction of generalised linear models and creation of 136 
funnel plots. 137 
Results 138 
Participants 139 
Over the 1 year of follow up analysed in this study, 36,206 ranibizumab injections were performed in 5,811 140 
eyes. Table 1 shows the baseline demographics of each of the 13 centres. The number of eyes treated 141 
ranged from 39 (Centre M) to 923 (Centre C). Patients treated at each centre were of similar age, ranging 142 
from a mean of 78.3 (J) to 81.7 years at the time of the first injection (K).  143 
Treatment and outcome characteristics of each centre are shown in Table 2. The median number of 144 
injections in each centre was 6 with one centre providing a median of 8 injections (J) and 2 centres 145 
providing a median of 5 (L, M). Mean starting VA across all centres was lowest in centre F (48.9 ETDRS 146 
letters) and highest in centre L (59.9 letters). VA after 12 months of treatment was highest in centre I (63.2 147 
letters) and lowest in centre M (52.9 letters). The centres with the higher mean starting VA did not 148 
necessarily finish 12 months with the highest VA at 1 year, nor did the centres with the lowest starting VA 149 
finish with the lowest VA at 1 year.  Centres that saw patients the most frequently (B) or injected most 150 
frequently (J) achieved the 5th and 2nd best VA at 1 year respectively and showed the least variation 151 
between 3 and 12 months. 152 
At 12 months, the mean change in VA across 13 centres varied from +6.9 letters (centre I) to -0.6 letters 153 
(centre L), a difference of 7.5 letters, with a mean VA gain of +2.5 letters. Figure 1 shows these results 154 
graphically, with further details in Table 2. The funnel plot in Figure 1 shows the distribution of centres and 155 
95% and 99% confidence intervals.  Two centres (L, D) were slightly outside the 99% confidence intervals; 156 
these were the only centres reporting a slight reduction in VA. One of these centres had the lowest number 157 
of injections (5, L); however the other centre had the median number of injections (6, D). Starting VA in 158 
centre D was near the middle of the distribution, at 53.7 letters, while in centre L, eyes commenced 159 
treatment with the best starting VA at 59.9 letters. In contrast, Figure 2 (supplement) shows that there was 160 
less variation in VA change from 0 to 3 months, with a tighter clustering of results. Figure 3 (supplement) 161 
shows the VA change from 3 months to 12 months, with most centres clustered within the 95% confidence 162 
intervals, and the previous 2 centres that were outside the 99% CI when considering change from 0-12 163 
months are now either within or very close to the limits (L, D).  164 
The proportion of eyes that gained 15 ETDRS letters or more at 12 months ranged from 7.7% (A) to 29.5% 165 
(K). When examined on the funnel plot (Figure 4 supplement), these proportions showed little variation 166 
from centre to centre, with all centres within or above the 99% CI. The proportion of eyes that lost 15 167 
ETDRS letters or more at 12 months showed an even tighter distribution, with all centres within the 99% CI, 168 
and all except one (L) within the 95% CI (Figure 5 supplement). The actual proportions ranged from 4.6% (I) 169 
to 11.7%(L). We also examined the proportion of eyes maintaining or achieving driving vision of 70 ETDRS 170 
letters or more and found all centres performed above the lower 99% CI limit.(Figure 6)  171 
It should be noted that the centre with the lowest number of visits and injections (M, median 9 visits, 172 
median 5 injections, Table 2) had outcomes in the middle of the distributions for all the VA measures 173 
studied (Figures 1-6). Similarly, the centres with the highest number of visits (B, 12 visits) and highest 174 
number of injections (J, 8 injections), generally had outcomes either in the middle of the distribution or 175 
higher than average but still within the 95% CI (Figures 1-6).  176 
We performed multivariable analyses to determine which factors were associated with better visual 177 
outcomes. Younger age, worse starting VA, and higher number of injections and visits but not gender were 178 
significantly associated with variation in these VA outcomes (P<0.01). Significant variation between centres 179 
persisted even after adjusting for these factors.   180 
Discussion 181 
There is considerable published data on VA outcomes derived from clinical trials but limited data describing 182 
real-world outcomes. Real-world outcomes indicating what is possible when trial results translate to clinical 183 
practice are ultimately the most important measure as they reflect what happens to whole populations of 184 
patients rather than the rarefied cohorts included in trials. They are also important for establishing 185 
benchmarks standards that are achievable in busy public systems, and for defining measures of quality care 186 
that take into account the heterogeneity of patient populations and care delivery systems. This study 187 
provides some of the first real-world outcomes from a single national health system, namely 13 UK public 188 
hospital centres using a PRN treatment posology. We report that there was some inter-centre variation in 189 
VA outcomes up to a maximum difference of 7.5 letters between the highest and lowest VA achieved from 190 
0-12 months. Age, starting VA, number of injections and visits but not gender were significantly associated 191 
with variation in these VA outcomes.  192 
The median performance of these 13 centres is comparable to results from clinical trials, once the lower 193 
starting VA and lower number of injections is taken into account. Table 3 compares findings from this study 194 
with clinical trial results. The CATT6and IVAN 7;9 studies achieved mean improvement from 0-12 months of 195 
6.8 and 5.0 letters, respectively with 7 injections, while the Groupe d’Etude Français Avastin versus Lucentis 196 
dans la DMLA néovasculaire (GEFAL)17  and Multicentre Anti-VEGF Trial in Austria (MANTA) 18 studies 197 
showed mean improvement of 2.9 and 4.1 letters respectively with 6 injections, as compared with mean 198 
improvement of 2.5 letters with 6 injections in this study. These results suggest that a similar benchmark of 199 
+2.5 letters improvement (0-12 months) with 6 injections represents quality ongoing care that is achievable 200 
in a real-world, public hospital setting. 201 
There are few other real-world studies with which to compare our results. A large database observational 202 
study from Australia, the Fight Retinal Blindness Study,19 reported mean VA gains of 5.3 letters after 2 years 203 
and 13 injections of a treat and extend posology. These results are superior to those achieved in this report 204 
but direct comparisons are difficult due to differences in health systems, patient mix, and different follow-205 
up periods.           206 
It should be noted that the difference in 0-12 month VA change between the highest and lowest scoring 207 
centres was 7.5 ETDRS letters, a difference that is only marginally beyond what some studies have 208 
considered non-inferior. The CATT6 and GEFAL17 considered a difference of 5 EDTRS letters to represent 209 
noninferiority, while the MANTA18 considered a difference of 7 letters to be noninferior.18  210 
Due to the ‘ceiling effect’ whereby eyes starting treatment with good VA have little room for further 211 
improvement, many measures are dependent on the starting VA.11;12;20 Adjusting for age, starting VA, 212 
number of injections and visits reduced, but did not eliminate the significant variation between centres, 213 
suggesting there are other unmeasured factors that contribute to these variations in outcomes.  214 
 215 
This study has several strengths including a large sequential sample, collection of a standardised minimum 216 
dataset as mandated by the use of an EMR reflecting routine, real-world clinical practice and the large 217 
number of centres involved. A weakness of this study is the loss to follow up of a number of patients over 218 
time, as is inevitable in a real-world clinical setting. Although there were differences in baseline 219 
demographics between patients lost to follow-up and those who completed follow-up, we have previously 220 
shown that VA changes are similar in both groups.11 Best-corrected VAs were not routinely measured, 221 
instead the VAs with habitual correction were reported in this study which may underestimate absolute VA 222 
measurements compared with clinical trials. It should be noted that clinical treatment decisions were based 223 
on these VAs and we believe these represent real-world outcomes and may better reflect patients’ visual 224 
experience than protocol determined best-corrected VAs. A possible reason for differences in injection 225 
numbers may be individual differences in centre / physician thresholds for retreatment using a PRN 226 
posology.    227 
 228 
In summary, we report that 13 UK centres using a PRN treatment posology for managing neovascular AMD 229 
achieved broadly similar VA outcomes with modest variability in outcomes. The difference between the 230 
highest and lowest VA gain at 12 months was 7.5 letters with a mean of +2.5 letters gained. Age, starting 231 
VA, number of injections and visits but not gender were significantly associated with variation in these VA 232 
outcomes.  These data may be considered as establishing an achievable benchmark for the quality of PRN 233 
posology in real-world settings, and is likely to be relevant to many sites worldwide.  234 
 235 
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  319 
Figure Legends. 320 
Figure 1: Funnel plot showing the change in ETDRS letters from baseline to 12 months by centre. Solid black 321 
lines represent the 95% confidence intervals, dashed lines the 99% confidence intervals. ETDRS refers to 322 
Early Treatment Diabetic Retinopathy Study. 323 
 324 
Figure 2 (supplement): Funnel plot showing the change in ETDRS letters from baseline to 3 months by 325 
centre. Solid black lines represent the 95% confidence intervals, dashed lines the 99% confidence intervals. 326 
ETDRS refers to Early Treatment Diabetic Retinopathy Study. 327 
 328 
Figure 3 (supplement): Funnel plot showing the change in ETDRS letters from 3 months to 12 months by 329 
centre. Solid black lines represent the 95% confidence intervals, dashed lines the 99% confidence intervals. 330 
ETDRS refers to Early Treatment Diabetic Retinopathy Study. 331 
 332 
Figure 4 (supplement): Funnel plot showing the proportion of eyes gaining 15 ETDRS letters or more from 333 
baseline to 12 months by centre. Solid black lines represent the 95% confidence intervals, dashed lines the 334 
99% confidence intervals. ETDRS refers to Early Treatment Diabetic Retinopathy Study. 335 
 336 
Figure 5 (supplement): Funnel plot showing the proportion of eyes losing 15 ETDRS letters or more from 337 
baseline to 12 months by centre. Solid black lines represent the 95% confidence intervals, dashed lines the 338 
99% confidence intervals. ETDRS refers to Early Treatment Diabetic Retinopathy Study. 339 
 340 
Figure 6: Funnel plot showing the proportion of eyes maintaining driving vision of 70 ETDRS letters or better 341 
at 12 months by centre.  Solid black lines represent the 95% confidence intervals, dashed lines the 99% 342 
confidence intervals. ETDRS refers to Early Treatment Diabetic Retinopathy Study.  343 
 344 
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